Agilent Technologies Inc. has recently signed a memorandum of understanding with Theragen Bio to advance bioinformatic technologies for cancer genomic profiling (CGP) by combining next generation sequencing (NGS) and bioinformatics capabilities. The partnership is expected to not only boost the NGS market in South Korea, but also improve cancer care by enabling personalized and faster treatment decisions, says GlobalData, a leading data and analytics company.

GlobalData’s report, “Next Generation Sequencing Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures and Forecast, 2015-2033,” reveals that that South Korea’s NGS tests market is projected to grow at a compound annual growth rate of around 6% between 2023 and 2030.

Agilent’s SureSelect CGP Assay panel is said to analyse 400 cancer-related genes and employs NGS to efficiently revolutionize translational research and clinical trials.

Shreya Jain, Medical Devices Analyst at GlobalData, comments: “The overwhelming revolution in NGS technology in recent years has greatly enhanced the understanding of cancer. NGS is now widely being implemented to identify specific tumor markers based on which targeted therapies and precision cancer treatment options can be tailored for improved patient outcomes.”

Agilent has made significant efforts to bring innovative technologies to patients with cancer and the laboratories across South Korea during the last three years. The strategic partnership with Theragen Bio, which has extensive bioinformatic analysis capabilities, is expected to further support Agilent’s commitment to providing improved access to personalized treatment.

Jain concludes: “NGS is closely linked to the implementation of precision medicine in cancer as it provides a more complete picture of cancer etiology than any other modality. However, significant challenges, particularly with respect to the data analysis and interpretation will have to be overcome to translate NGS to the bedside of cancer patients.”